Home Latest News Biannual Injection Found to Be Completely Effective in Preventing HIV Infection: Study
Latest News

Biannual Injection Found to Be Completely Effective in Preventing HIV Infection: Study

Share
HIV
Share

A recent study has found that biannual injections of lenacapavir, a drug currently used to treat HIV, are highly effective in preventing infections among young women and adolescent girls in Africa. Data released by drugmaker Gilead and published in the New England Journal of Medicine revealed that lenacapavir demonstrated 100% efficacy in preventing HIV infections during a Phase 3 trial.

Traditionally, HIV prevention has relied on daily medications such as Truvada or bimonthly injections of Apretude. The introduction of lenacapavir, with its twice-yearly dosage, could revolutionize prevention methods, offering a new, highly effective option.

The PURPOSE 1 trial involved over 5,000 HIV-negative women and adolescent girls in South Africa and Uganda. Participants were randomly assigned to receive either lenacapavir injections every 26 weeks or daily HIV medications. In this double-blind study, none of the participants who received lenacapavir contracted HIV. These findings were also presented at the International AIDS Conference in Munich.

Linda-Gail Bekker, director of the Desmond Tutu HIV Center at the University of Cape Town, highlighted the significance of these results, stating, “These stellar results show that twice-yearly lenacapavir for PrEP, if approved, could offer a highly effective, tolerable, and discreet choice that could potentially improve PrEP uptake and persistence, helping us to reduce HIV in cisgender women globally.”

Although about 69% of those who received lenacapavir experienced reactions at the injection site compared to 35% in the placebo group, no significant safety concerns were reported. Over the 26-week trial period, 55 HIV infections were observed: zero in the lenacapavir group, 39 in the daily emtricitabine–tenofovir alafenamide group, and 16 in the daily emtricitabine–tenofovir disoproxil fumarate group.

While lenacapavir is not yet approved for HIV prevention anywhere in the world, it is approved by the US Food and Drug Administration (FDA) for treating HIV in adults, in combination with other antiretroviral medicines. The drug’s cost is estimated to be over $40,000 annually as a manufacturer’s list price, or around $39,000 annually as an average wholesale price. As lenacapavir continues to be studied for HIV prevention, questions about its cost and accessibility remain.

Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss

Bundibugyo Ebola virus
International NewsVirus & DiseaseWHO

From Fever To Organ Failure: How The Bundibugyo Ebola Virus Affects The Body

The Bundibugyo Ebola virus outbreak has raised fresh global health concerns as infections continue to spread across parts of Central and East Africa....

WHO
Health TipsInternational NewsLatest NewsLifestyle & WellnessWHO

WHO Issues First Type 1 Diabetes Guidelines for Adults: 7 Things Patients Need to Know

More than 100 years after the discovery of insulin, millions of people living with type 1 diabetes continue to face challenges in accessing...

Breast Cancer
Health NewsOncology

Mammogram vs Ultrasound vs MRI: Which Breast Cancer Screening Test Is Right for You?

Breast cancer is one of the most common cancers affecting women worldwide, and early detection plays an important role in improving treatment outcomes....

Always Tired? It Could Be Anaemia!
Diet & NutritionHealth NewsHealth TipsLifestyleLifestyle & WellnessWellness

Anaemia in India: Why Iron Deficiency Remains a Concern and 7 Signs You Should Not Ignore

Feeling tired all the time, experiencing frequent dizziness or getting breathless after climbing a few stairs? While these symptoms are often dismissed as...

N95 Mask
Health TipsLatest NewsLifestyle & WellnessWellness

Does Wearing an N95 Mask Protect You From PM2.5 Pollution? Doctors Explain How To Choose And Wear It Correctly

As air pollution continues to affect several Indian cities during winter, wearing a mask has become an important precaution for people stepping outdoors....

Section title

Related Articles
Latest NewsWHO

WHO Releases First-Ever Guidelines For Type 1 Diabetes In Adults: 5 Key Recommendations Explained

The World Health Organization (WHO) has issued its first-ever guidelines for the...

Health NewsLatest NewsLifestyle

7 Simple Ways to Protect Yourself from Air Pollution

Air pollution has become a major health concern today. Dust from construction...